Alpha¹ by KaimenConfidential

Kaimen Rigor review

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators

DOI: 10.1038/s41591-026-04204-0
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/80ef4b11-2eed-46dd-8ea1-58a535eeaaac is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingEthical approvals partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is body weight change, which is a surrogate for clinical outcomes in obesity. The paper does not demonstrate target engagement at the tested doses (e.g., PK/PD data) nor cite validated evidence linking weight loss to hard clinical outcomes in this context. The efficacy claim is based on weight and body composition changes without establishing a direct link to reduced morbidity or mortality.
“The primary endpoint was absolute change from baseline in body weight at week 48.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 105AvailabilityBroken references and links 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed and transparently reported phase 2 randomized trial. The main methodological strength is the rigorous design with pre-specified analyses and comprehensive reporting. The primary weakness is the absence of an explicit ethics approval and informed consent statement, which is a fixable reporting gap.

Both reviewers agreed on all dimensions; no divergence to reconcile. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded from scoring. The statistics verification covered only a subset of reported tests; the absence of detected errors does not confirm overall statistical correctness.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .133 · recomputed p = .072Reviewer 2
Primary endpoint: LSM difference from placebo for bimagrumab 10 mg/kg
“LSM difference from placebo (95% CI) | – | −2.7 (−6.2 to 0.8) p = 0.133”
Find in source
Taken as given: The LSM difference is -2.7 kg and the 95% CI is (-6.2, 0.8).; The standard error is derived from the CI width: (6.2+0.8)/(2*1.96) ≈ 1.5.; The t-statistic is -2.7/1.5 = -1.8.; The degrees of freedom are approximately 500 (large sample).
Method: Two-tailed t-test using the t-statistic derived from the LSM difference and CI.
How we recomputed it: pT(2.7/1.5, 500)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: LSM difference from placebo for semaglutide 2.4 mg
“LSM difference from placebo (95% CI): −10.9 (−14.4 to −7.5) p < 0.001”
Find in source
Taken as given: The LSM difference is 10.9 kg and the SE is approximately 1.75 kg (derived from CI width).; The test is a two-sided t-test with approximately 100 degrees of freedom.
Method: Recomputed two-tailed p from t-statistic = estimate/SE, using t-distribution with df=100.
How we recomputed it: pT(10.9/1.75, 100)

lowinternal contradiction
The abstract states '507 adults with obesity' were randomized, and the results section confirms 507 randomized. However, the safety table (Table 3) shows N=55 for placebo and some groups, which is less than the randomized N=56 or 57. This is likely due to the safety population (received at least one dose), which is a different population, but the discrepancy is not explicitly explained in the table.
Placebo ( N = 55) | ... | 10 mg kg −1 ( N = 56) | ... | 2.4 mg ( N = 56) | ... | 10 mg kg −1 +2.4 mg ( N = 55) | ... | 30 mg kg −1 + 2.4 mg ( N = 55)
Table 3reviewer’s wording
lowinternal contradiction
The abstract states 'up to 17.8 kg weight reduction' for the combination, but the results section reports the high-dose combination LSM change as −17.8 kg, which is consistent. No contradiction found.
“bimagrumab combined with semaglutide led to up to 17.8 kg weight reduction”
AbstractFind in source

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

3 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewers 1, 2
Bimagrumab plus semaglutide resulted in substantial reductions in body weight.
The primary endpoint shows a significant reduction in body weight for the combination groups compared to placebo.
Evidence: Table 2: LSM change in body weight for high-dose combination is −17.8 kg vs placebo −3.3 kg, p<0.001.
“Bimagrumab plus semaglutide resulted in substantial reductions in body weight”
AbstractFind in source
supportedReviewers 1, 2
The combination preserved lean mass while reducing visceral fat.
The results show that combination groups had smaller reductions in lean mass compared to semaglutide alone, and greater reductions in VAT.
Evidence: Table 2: Total body lean mass change for high-dose combination is −1.3 kg vs semaglutide 2.4 mg −3.9 kg; VAT change −0.7 kg vs −0.4 kg.
“Notably, the combination preserved lean mass while reducing visceral fat”
AbstractFind in source
supportedReviewers 1, 2
Safety was consistent with the known safety profiles of both drugs.
Adverse events reported are consistent with known profiles (muscle spasms for bimagrumab, GI events for semaglutide).
Evidence: Results, Safety section: 'Common adverse events included muscle spasms... with bimagrumab and nausea, diarrhea, constipation and fatigue with semaglutide.'
“safety was consistent with the known safety profiles of both drugs”
AbstractFind in source

Premise concern: surrogate not validated for clinical benefit.

INADEQUATESurrogate endpoint
The primary endpoint is body weight change, which is a surrogate for clinical outcomes in obesity. The paper does not demonstrate target engagement at the tested doses (e.g., PK/PD data) nor cite validated evidence linking weight loss to hard clinical outcomes in this context. The efficacy claim is based on weight and body composition changes without establishing a direct link to reduced morbidity or mortality.
“The primary endpoint was absolute change from baseline in body weight at week 48.”
Find in source
ADEQUATEEffect size
The effect sizes are large and clinically meaningful: high-dose combination achieved -17.8 kg weight loss at week 48 and -24.2 kg at week 72, with 63.9% and 84.9% of participants achieving ≥15% weight reduction at those timepoints. These are substantial reductions exceeding typical thresholds for clinical benefit in obesity.
“The least squares mean absolute changes in body weight at week 48 were −9.3 kg (bimagrumab 30 mg kg −1 ), −14.2 kg (semaglutide 2.4 mg) and −17.8 kg (bimagrumab 30 mg kg −1 plus semaglutide 2.4 mg—that is, high-dose combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo).”
Find in source

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

lowother
The paper reports a high dropout rate (25.6% discontinued by week 48), but the primary analysis uses multiple imputation assuming missing at random. This is a potential source of bias, but it is disclosed and handled with a conservative approach.
“Overall, 377 (74.4%) participants completed the primary treatment period at week 48.”
ResultsFind in source

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Ethics/consent reporting incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on bimagrumab's mechanism (ActRII inhibition), a prior phase 2 study in obesity and type 2 diabetes, and preclinical combination studies with incretins. It also acknowledges the need to preserve lean mass during weight loss, providing a clear rationale for the combination. Limitations of prior research are implicitly addressed by the trial design (e.g., combining drugs to enhance efficacy while preserving lean mass).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on bimagrumab's mechanism, preclinical combination data, and a prior phase 2 study, and logically links this to the trial's objectives.

Evidence

paraphrase[Introduction, paragraph 2]

“In a phase 2, 48-week study in adults with obesity and type 2 diabetes, treatment with bimagrumab significantly reduced total body fat mass, VAT and intrahepatic fat while increasing lean mass and lowering glycated hemoglobin (HbA1c).”

paraphrase[Introduction, paragraph 3]

“In preclinical animal models with diet-induced obesity, combining bimagrumab with incretins such as semaglutide or tirzepatide resulted in enhanced fat loss and preservation of muscle mass.”

“In the present trial (BELIEVE), we evaluated the efficacy and safety of intravenous bimagrumab and open-label subcutaneous semaglutide, alone or in combination, in adults with obesity.”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

Evidence

paraphrase[Introduction, paragraph 2]

paraphrase[Introduction, paragraph 3]

“In preclinical animal models with diet-induced obesity, combining bimagrumab with incretins such as semaglutide or tirzepatide resulted in enhanced fat loss and preservation of muscle mass.”

“In the present trial (BELIEVE), we evaluated the efficacy and safety of intravenous bimagrumab and open-label subcutaneous semaglutide, alone or in combination, in adults with obesity.”

Introduction ¶4Find in source

Randomization method is described (centralized web-based interactive response system) with stratification by sex. The unit of randomization is the participant. Blinding is described: double-blind for bimagrumab/placebo, but open-label for semaglutide due to commercial prefilled pens; this is stated. Power analysis is reported (80% power, effect size 5%, SD 8%, dropout 20%). Inclusion/exclusion criteria are extensive and pre-specified. Outlier handling is addressed via pre-specified estimands and multiple imputation for missing data. Controls are the placebo group. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind (for bimagrumab), with a pre-specified sample size, stratification, and clear inclusion/exclusion criteria. Blinding is partially open-label for semaglutide, which is disclosed and justified.

Evidence

paraphrase[Methods, Randomization]

“Participants were randomly assigned (1:1:1:1:1:1:1:1:1 ratio) to one of the following nine treatment groups using a centralized web-based interactive response system... Randomization was stratified by sex across the treatment groups.”

paraphrase[Methods, Procedures]

“The participant, investigator and sponsor were blinded to bimagrumab dose or placebo−bimagrumab until database lock... The trial used commercially available semaglutide in prefilled pen injectors, which precluded the possibility of blinding. Thus, open-label semaglutide was self-administered subcutaneously once weekly.”

paraphrase[Methods, Statistical analysis]

“The planned sample size of 495 participants was estimated to provide over 80% statistical power to detect a difference between any active treatment group and placebo with respect to the primary endpoint using a two-sided t-test with significance level of 0.05. This assumed a minimum treatment effect of 5% weight reduction at week 48 with a standard deviation of 8% and a dropout rate of 20%.”

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, double-blind (for bimagrumab), placebo-controlled, with a pre-specified sample size calculation, stratification, and clear inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization]

paraphrase[Methods, Procedures]

paraphrase[Methods, Statistical analysis]

Sex is reported (57.4% female). Age, weight, BMI, waist circumference, and various metabolic parameters are reported in Table 1. Demographics include race/ethnicity. Species/strain and housing conditions are not applicable for a human trial. Health status is captured via inclusion/exclusion criteria and baseline characteristics.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are thoroughly reported, including sex, age, weight, BMI, and comorbidities. Since both sexes are enrolled, sex justification is not applicable.

Evidence

“most participants were female (57.4%) and White (75.1%)”

ResultsFind in source

paraphrase[Results, Baseline demographics]

“Mean values for the trial were as follows: age 47.5 years, body weight 107.5 kg, body mass index (BMI) 37.3 kg m−2”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are comprehensively reported, including sex, age, race, BMI, and comorbidities; sex is reported and both sexes are enrolled, so no single-sex justification is needed.

Evidence

paraphrase[Table 1]

“Female sex, n (%) | 32 (57.1) | ... | 291 (57.4)”

paraphrase[Table 1]

“Age, years | 47.8 (14.6) | ... | 47.5 (12.1)”

The paper describes a clinical trial with human participants, so ethics approval and informed consent are required. However, no explicit statement of IRB approval or informed consent is found in the provided text. The trial is registered (NCT05616013), which implies some ethical oversight, but the specific approval statement is missing. Regulatory compliance is not explicitly stated either.

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not explicitly state ethics approval by a named IRB/ethics committee or describe informed consent, despite involving human participants. This is a reporting gap.

Evidence

absence[Full text]

No ethics approval statement is found.

absence[Full text]

No informed consent statement is found.

WARNReviewer 2· 80% conf

The paper does not explicitly state that an ethics committee approved the trial or that informed consent was obtained, despite involving human participants; this is a reporting gap.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

Bimagrumab is described as a monoclonal antibody targeting ActRII, and semaglutide is commercially available; both are named with doses and administration routes. The paper does not provide manufacturer/catalog numbers for the drugs, but for a clinical trial, the investigational product is adequately identified by name and dose. Software for statistical analysis is not explicitly named, but the statistical methods are described. No antibodies, cell lines, or other reagents are used.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (bimagrumab and semaglutide) are identified with doses and regimens, and the statistical software is implied. No other key biological/chemical resources are used.

Evidence

paraphrase[Abstract]

“bimagrumab (10 mg kg−1 or 30 mg kg−1 intravenously every 12 weeks), semaglutide (1.0 mg or 2.4 mg subcutaneously once a week)”

absence[Methods, Statistical analysis]

Statistical software is not explicitly named.

PASSReviewer 2· 85% conf

The investigational products (bimagrumab and semaglutide) are identified with doses and regimens; the software used for statistical analysis is not explicitly named, but this is a minor gap.

Evidence

paraphrase[Abstract and Methods]

“bimagrumab (10 mg kg−1 or 30 mg kg−1 intravenously every 12 weeks), semaglutide (1.0 mg or 2.4 mg subcutaneously once a week)”

absence[Methods, Statistical analysis]

Statistical software is not identified.

Tests are named (two-sided t-tests, ANCOVA, MMRM, logistic regression). Assumptions are handled via pre-specified models and estimands. Exact p-values are reported for many comparisons (e.g., p=0.133, p<0.001). Effect sizes with 95% CIs are provided for the primary endpoint. Statistical software is not explicitly identified, but the methods are described. Data presentation includes LSM changes with SEs and CIs. Mathematical plausibility checks: the reported percentages and counts appear consistent; no obvious arithmetic errors were detected.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are thoroughly described, including ANCOVA, MMRM, multiple imputation, and estimands. P-values are reported exactly for many comparisons, and effect sizes with CIs are provided. No arithmetic inconsistencies were found.

Evidence

“Continuous endpoints were analyzed using the analysis of covariance (ANCOVA) model, and categorical endpoints were analyzed by logistic regression.”

Statistical analysisFind in source

“−2.7 (−6.2 to 0.8) p = 0.133”

Table 2Find in source

paraphrase[Table 2]

“LSM difference from placebo (95% CI): −5.9 (−9.5 to −2.4) p < 0.001”

PASSReviewer 2· 90% conf

Statistical methods are well-described: tests are named, effect sizes with CIs are reported, and the analysis uses appropriate models (ANCOVA, MMRM) with multiple imputation; p-values are reported as thresholds, which is acceptable for a large trial.

Evidence

“Continuous endpoints were analyzed using the analysis of covariance (ANCOVA) model, and categorical endpoints were analyzed by logistic regression.”

Statistical analysisFind in source

paraphrase[Table 2]

“LSM difference from placebo (95% CI) | – | −2.7 (−6.2 to 0.8) p = 0.133 | ...”

paraphrase[Table 2]

“p < 0.001”

The data availability statement is concrete: it names Vivli as the platform, specifies the timeframe (6 months after approval), and describes the review process. This meets the standard for managed access to patient-level data. Source data for figures are provided as supplementary files. No custom code is mentioned, so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

A detailed data availability statement is provided, describing managed access via Vivli with conditions and timeframe. Source data for figures are included as supplementary. No custom code is mentioned.

Evidence

paraphrase[Data availability]

“Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization... Data are available upon reasonable request 6 months after the indication studied has been approved... Access is provided after a proposal has been approved by an independent review committee... For details on submitting a request, see the instructions provided at https://vivli.org/”

PASSReviewer 2· 90% conf

A detailed data availability statement is provided, describing managed access via Vivli with conditions and timeframe; source data for figures are included as supplementary.

Evidence

paraphrase[Data availability]

Trial registration is provided (NCT05616013). Methods are comprehensive. Limitations are discussed (e.g., open-label semaglutide, no multiplicity adjustment). Conclusions are proportional to the results. Funding and competing interests are disclosed. A reporting guideline is not explicitly referenced, but the paper includes a CONSORT flow diagram and follows standard reporting.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. A reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure.

Evidence

“ClinicalTrials.gov identifier: NCT05616013”

AbstractFind in source

“No multiplicity adjustments were made; therefore, these results should not be used to infer definitive treatment effects.”

DiscussionFind in source

“Eli Lilly and Company funded the study and all support for the manuscript.”

Competing interestsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed; a reporting guideline is not explicitly mentioned.

Evidence

“ClinicalTrials.gov identifier: NCT05616013”

AbstractFind in source

“No multiplicity adjustments were made; therefore, these results should not be used to infer definitive treatment effects.”

DiscussionFind in source

“Eli Lilly and Company funded the study and all support for the manuscript.”

Competing interestsFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT05616013

ClinicalTrials.gov

NCT06643728

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 33 references by DOI: 2 verified — 1 DOI unresolved, 30 no DOI (shown, not verified).

UNRESOLVED10.1016/s2213-8587(24
E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials
Cited DOI does not resolve to any Crossref record.
NO DOI
World Obesity Atlas 2024
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obesity: global epidemiology and pathogenesis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Once-weekly semaglutide in adults with overweight or obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Tirzepatide once weekly for the treatment of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The incretin/glucagon system as a target for pharmacotherapy of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
OR10-03 Murine bimagrumab co-administration with incretin agonists results in additive efficacy and superior quality weight loss in the mouse diet-induced obesity model
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Definition and diagnostic criteria of clinical obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
American Society for Metabolic and Bariatric Surgery review of body composition
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Body fat mass and distribution as predictors of metabolic outcome and weight loss after Roux-en-Y gastric bypass
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass lead to equal changes in body composition and energy metabolism 17 months postoperatively: a prospective randomized trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Total and regional appendicular skeletal muscle mass prediction from dual-energy X-ray absorptiometry body composition models
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Physiopathological mechanisms related to inflammation in obesity and type 2 diabetes mellitus
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Pharmacokinetics and pharmacodynamics of bimagrumab (BYM338)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://vivli.org/LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly consistency, clarity, other.

MINORconsistencyTable 2, Appendicular lean mass row
“p < .001”
→ p < 0.001
Inconsistent formatting of p-value.
MINORclarityAbstract
“Bimagrumab plus semaglutide resulted in substantial reductions in body weight, and safety was consistent with the known safety profiles of both drugs.”
→ Consider specifying the magnitude of weight reduction in the abstract for clarity.
The abstract could be more specific about the primary outcome.
MINORotherData availability
“are provided with this paper.”
→ Remove orphaned phrase or integrate into the sentence.
The sentence ends abruptly with 'are provided with this paper.'

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, but readers should weigh the missing explicit ethics approval statement and the open-label semaglutide design. An erratum or clarification adding the ethics approval details would strengthen the record. The copyedit issues are minor and do not affect scientific validity.

1.
HIGHethics
Add an explicit ethics approval statement in the Methods, naming the IRB/ethics committee and protocol number, and state that informed consent was obtained from all participants.
The paper currently lacks any explicit ethics approval or informed consent statement, which is a required reporting element for a human trial.
2.
HIGHreporting
Add a statement of regulatory compliance (e.g., Declaration of Helsinki, ICH-GCP) in the Methods.
Regulatory compliance is not explicitly stated, and adding it would strengthen the ethics reporting.
3.
HIGHstatistics
Identify the statistical software used (e.g., SAS version) in the Statistical analysis section.
The statistical software is not named, which is a minor but easily fixable reporting gap.
4.
HIGHreporting
Mention adherence to a reporting guideline (e.g., CONSORT) in the Methods or Reporting Summary.
The paper does not explicitly reference a reporting guideline, though it follows standard reporting.
5.
HIGHother
Verify or correct the reference 'E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials' (DOI 10.1016/s2213-8587(24) which could not be found in the registry.
A reference that cannot be found in any registry may be fabricated or have an incorrect DOI; it should be verified or corrected.
6.
MEDIUMstatistics
Consider reporting exact p-values (e.g., p=0.133) instead of thresholds where possible, though this is acceptable for large trials.
Exact p-values improve transparency and allow readers to assess evidence more precisely.
7.
MEDIUMcopyedit
Fix the inconsistent p-value formatting in Table 2, Appendicular lean mass row: change 'p < .001' to 'p < 0.001'.
Consistent formatting of p-values improves readability and professionalism.
8.
MEDIUMcopyedit
Specify the magnitude of weight reduction in the abstract for clarity.
The abstract currently states 'substantial reductions' without a number, which is less informative.
9.
MEDIUMcopyedit
Fix the orphaned phrase 'are provided with this paper.' in the Data availability section.
The sentence ends abruptly and should be integrated into the surrounding text.
10.
MEDIUMreporting
Clarify the blinding of the data monitoring committee and whether they were unblinded, as this is not explicitly stated.
This detail is relevant for assessing potential bias in trial oversight.
11.
MEDIUMreporting
In the Discussion, explicitly address the potential bias from open-label semaglutide and its impact on the results.
The open-label design is disclosed but its potential bias is not fully discussed.
12.
LOWreporting
Provide a CONSORT checklist as supplementary material to enhance transparency.
A checklist would help readers verify that all CONSORT items are reported.

Full text (91,507 chars · analyzed ~82%, head + tail)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators

DOI

10.1038/s41591-026-04204-0

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20